Autologous Dendritic Cell Therapy in Mesothelioma Patients Enhances Frequencies of Peripheral CD4 T Cells Expressing HLA-DR, PD-1, or ICOS-Reference-Cited by-同舟云学术

Autologous Dendritic Cell Therapy in Mesothelioma Patients Enhances Frequencies of Peripheral CD4 T Cells Expressing HLA-DR, PD-1, or ICOS

Published:2018-09-07 Issue: Volume:9 Page:
ISSN:1664-3224
Container-title:Frontiers in Immunology
language:
Short-container-title:Front. Immunol.

Author:

de Goeje Pauline L.,Klaver Yarne,Kaijen-Lambers Margaretha E. H.,Langerak Anton W.,Vroman Heleen,Kunert André,Lamers Cor H. J.,Aerts Joachim G. J. V.,Debets Reno,Hendriks Rudi W.

Funder

KWF Kankerbestrijding

ZonMw

Publisher

Frontiers Media SA

Subject

Immunology,Immunology and Allergy

Reference31 articles.

1. Novel insights into mesothelioma biology and implications for therapy;Yap;Nat Rev Cancer,2017

2. Treatment patterns and survival analysis in 9014 patients with malignant pleural mesothelioma from Belgium, the Netherlands and England;Damhuis;Lung Cancer,2015

3. Checkpoint blockade in lung cancer and mesothelioma;Lievense;Am J Respir Crit Care Med,2017

4. Neutralizing tumor-promoting chronic inflammation: a magic bullet?;Coussens;Science,2013

5. The tumoral and stromal immune microenvironment in malignant pleural mesothelioma: a comprehensive analysis reveals prognostic immune markers;Ujiie;Oncoimmunology,2015

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dendritic cells loaded with allogeneic tumour cell lysate plus best supportive care versus best supportive care alone in patients with pleural mesothelioma as maintenance therapy after chemotherapy (DENIM): a multicentre, open-label, randomised, phase 2/3 study;The Lancet Oncology;2024-07

2. Adjuvant dendritic cell-based immunotherapy after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with malignant peritoneal mesothelioma: a phase II clinical trial;Journal for ImmunoTherapy of Cancer;2023-08

3. Autologous dendritic cells pulsed with allogeneic tumour cell lysate induce tumour-reactive T-cell responses in patients with pancreatic cancer: A phase I study;European Journal of Cancer;2022-07

4. Mesothelin‑specific T cell cytotoxicity against triple negative breast cancer is enhanced by 40s ribosomal protein subunit 3‑treated self‑differentiated dendritic cells;Oncology Reports;2022-05-25

5. Current research status of HLA in immune‐related diseases;Immunity, Inflammation and Disease;2021-03-03